Hypofractionated Radiosurgery to Treat Residual/Recurrent Non Secreting Pituitary Adenoma (HYPOADENO)
Key facts
- Who runs it
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 25 people enrolled
- Started
- 14 Sept 2020
- Ended
- 20 May 2025
- Type of study
- Interventional
- Treatments tested
- hypofractionated radiosurgery
- Record updated
- 30 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Residual or progressive non secreting pituitary adenoma
- Exclusion of other treatment approach (second surgery, wait and scan; suppressive therapy) by a multidisciplinary team
- Age ≥ 18 years; KPS ≥ 70
- Written privacy consent
- Ability to give informed consent
Who cannot take part
- Previous cranial irradiation
- Diagnosis of secreting adenoma
- pregnancy status
- unable to undergo MRI or CT scans
- unable to give informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Single session stereotactic radiosurgery (SRS) is commonly used for patients with non-functioning adenomas. However the SRS can be limited by the proximity of the tumor with the surrounding critical structures (i.e., the optic chiasm).
Read full original descriptionShow less
The goal of the present prospective phase II trial is to investigate early and early delayed toxicity for cranial nerves and pituitary function after hypofractionated stereotactic radiotherapy/multisession radiosurgery (hSFRT/mSRS) in residual/ recurrent non secreting pituitary adenomas. Secondary end points are late toxicity and tumour growth local control.
All the enrolled patients will undergo radiosurgical treatment with a hypofractionation schedule Following radiotherapy, follow-up will be scheduled every 6 months during the first year post-radiosurgery and then annually, with the same tests.
The baseline examination and the follow-up assessment will include magnetic resonance imaging (MRI), full blood counts and blood chemistry tests, neuro-ophtalmology evaluation, physical and psychological examination that included a quality-of-life (EORTC Quol 30; BN 20) and a Hospital Anxiety and Depression Scale (HADS).
The group in the trial
- RadiosurgeryTreatment being tested
Patients suffering from residual/recurrent non functioning pituitary adenoma wil undergo to hypofractionated radiosurgery
Treatment: hypofractionated radiosurgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY/MULTISESSION RADIOSURGERY (HSFRT/MSRS) IN RESIDUAL/ RECURRENT NON SECRETING PITUITARY ADENOMAS AN EXPLORATORY STUDY
- Record updated
- 30 March 2026